Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Teva Pharmaceutical Industries ADR (NY: TEVA ) 17.75 +0.02 (+0.14%) Streaming Delayed Price Updated: 11:22 AM EDT, Sep 25, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Teva Pharmaceutical Industries ADR < Previous 1 2 3 4 5 6 7 8 9 ... 23 24 Next > As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse September 24, 2024 EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:NTRBW),(NYSE:TEVA),(NYSE:LLY),(NYSE:NVS),(NASDAQ:AMRX) EQNX::TICKER_END Via FinancialNewsMedia Exposures Product Safety As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse September 24, 2024 From FN Media Group LLC Via GlobeNewswire If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,400 Today September 16, 2024 Via Benzinga Key Takeaways From Teva Pharmaceutical Indus Analyst Ratings September 03, 2024 Via Benzinga $1000 Invested In This Stock 5 Years Ago Would Be Worth $2,400 Today August 21, 2024 Via Benzinga Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia September 23, 2024 From Teva Pharmaceutical Industries Ltd Via GlobeNewswire Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia September 21, 2024 From Teva Pharmaceutical Industries Ltd Via GlobeNewswire Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings July 29, 2024 The unfolding week's market trajectory depends on earnings from bellwether tech stocks and what the Fed has to say following its July meeting. Via Benzinga Topics Economy Exposures Interest Rates New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000) September 21, 2024 From Teva Pharmaceutical Industries Ltd Via GlobeNewswire Teva to Present at the Bank of America 2024 Global Healthcare Conference September 11, 2024 From Teva Pharmaceutical Industries Ltd Via GlobeNewswire UnitedHealth Follows Competitors, Replaces Humira with Lower-Cost Biosimilars September 11, 2024 UnitedHealth will remove AbbVie's Humira from its preferred drug lists by 2025, opting for lower-cost biosimilars like Amgen's Amjevita, in a move aimed at cutting prescription costs. Via Benzinga Teva Announces $80M Settlement To Baltimore: City Continues Opioid Litigation Against Other Companies September 10, 2024 Baltimore secures an $80 million settlement with Teva Pharmaceuticals in its opioid crisis litigation. Funds will be allocated to education, recovery centers, and outreach initiatives. Via Benzinga JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability September 06, 2024 JP Morgan assesses the specialty pharma sector, highlighting robust fundamentals and new product excitement. Key focus on Teva, Organon, and Viatris. Via Benzinga Shortage Relief: More Takeda's Vyvanse For ADHD On the Way As US Ramps Up Production September 06, 2024 Increase in production of Takeda's ADHD drug Vyvanse, approved by DEA to address ongoing shortages both domestically and globally. Via Benzinga Organon Stock Sees Relative Strength Rating Rise To 91 August 27, 2024 On Tuesday, Organon[ stock hit an key technical milestone, seeing its Relative Strength Rating jump to 91, up from 88 the day before. Via Investor's Business Daily Teva to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference August 26, 2024 From Teva Pharmaceutical Industries Ltd Via GlobeNewswire Novo Nordisk's Ozempic Might Be Among 2027 Medicare Price Negotiation Targets August 23, 2024 Analysts expect Novo Nordisk's Ozempic and other major drugs to be included in 2027 Medicare price negotiations. Despite concerns, experts predict limited financial impact on companies like Pfizer,... Via Benzinga Organon Stock Earns Relative Strength Rating Upgrade; Hits Key Threshold August 20, 2024 On Tuesday, generic drug maker Organon stock had its Relative Strength (RS) Rating upgraded to 83, up from 78 a day earlier. Via Investor's Business Daily $100 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth This Much Today August 13, 2024 Via Benzinga The 7 Best Under $20 Stocks to Buy in August 2024 August 07, 2024 Although cheap stocks are often cheap for a reason, it doesn't hold true for the best stocks under $20, which is where investors can profit. Via InvestorPlace Revolutionary Magnetic Therapy Could Speed Up Bipolar Treatment August 06, 2024 New research suggests that powerful magnets could effectively treat bipolar disorder. This therapy, which is known as accelerated intermittent theta burst stimulation (iTBS), uses magnetic waves... Via PressReach Exposures Product Safety What Are the Hottest Biotech Stocks Right Now? 3 Top Picks. August 02, 2024 Figuring out the hottest biotech stocks can be as simple as looking at the most traded stocks by volume in the last 24 hours. Via InvestorPlace Tech Stocks On Track For Best Session In 5 Months Ahead Of Fed Meeting; Small Caps Target Highest Close Since January 2022: What's Driving Markets Wednesday? July 31, 2024 Tech stocks soared to their best session in five months on Wednesday, ahead of the highly anticipated Federal Open Market Committee (FOMC) meeting. Via Benzinga Topics Economy Exposures Interest Rates Match Group Posts Upbeat Sales, Joins Modine Manufacturing, Scotts Miracle-Gro, NVIDIA And Other Big Stocks Moving Higher On Wednesday July 31, 2024 Via Benzinga Teva Pharmaceutical Industries (TEVA) Q2 2024 Earnings Call Transcript July 31, 2024 TEVA earnings call for the period ending June 30, 2024. Via The Motley Fool Topics Earnings Exposures Financial Teva Beats Q2 Estimates, Raises Annual Outlook On Strong Generic, Austedo Sales July 31, 2024 Teva Pharmaceutical reported Q2 2024 sales of $4.16 billion, surpassing the $4.06 billion consensus. Revenue rose 7% YoY, driven by growth in generic products and Austedo sales. Adjusted EPS was $0.61,... Via Benzinga Teva Pharma Flirts With Breakout As Generic Drugs Drive Beat-And-Raise July 31, 2024 The company now expects $16 billion to $16.4 billion in full-year sales. Via Investor's Business Daily Teva Announces Strong Growth in Second Quarter Revenues mainly driven by Generics Products in All Regions and AUSTEDO®; Raises 2024 Financial Guidance July 31, 2024 From Teva Pharmaceutical Industries Ltd Via GlobeNewswire Wall Street Remains On Track For AMD-Led Rebound Ahead Of Fed Decision, Meta Earnings: Analyst Says 'The Bull Tends To Remain' Despite Near-Time Volatility July 31, 2024 Tech optimism is likely to abound on Wall Street as AI-levered stocks are feeding off the strength generated by Advanced Micro Devices, Inc.‘s (NASDAQ:AMD) Via Benzinga Topics Economy Exposures Interest Rates 10 Health Care Stocks Whale Activity In Today's Session July 30, 2024 Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 ... 23 24 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.